Godrej Agrovet / Q3-FY26

GODREJAGRO Q3 FY26 earnings call.

A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.

Research layer active

ConCallIQ research layer

Signal, with the source still visible.

Use the controls below to narrow the view, then follow the evidence into the next layer of context.

Positive2026-01-23Back to GODREJAGRO

Revenue

₹2,718 Cr

verified against source

Revenue YoY

11%

reported change

EBITDA

Pending

latest reported figure

Source

screener in

record provenance

Actual signal trajectory

Where this quarter sits.

source records only
Revenue (₹ Cr)PositiveWatchNegative
2 actual records
Actual quarterly Revenue (₹ Cr) trajectoryReported values plotted by quarter. Hover or focus a point for its quarter, value, and source sentiment.Q3 FY26: 2,718 · Positive source sentiment · 2026-01-23Q3 FY26Q1 FY27: 2,852 · Watch source sentiment · 2026-07-14Q1 FY272,8522,718
Values are taken from the available verified source records; sentiment color is a separate source-read indicator.

Quarter read

What the record says.

Godrej Agrovet delivered a strong Q3 FY26 with consolidated revenues growing 11% YoY and profit before tax up 23% YoY (before exceptional items). The performance was driven by margin expansion, operational efficiencies, and robust contributions from vegetable oil, animal feed, poultry, and processed foods, alongside a sharp turnaround in Astec Life Sciences. Animal feed volumes grew 12% YoY, with cattle feed up 21%, while vegetable oil revenue rose 27% on higher fresh fruit bunch arrivals and record oil extraction ratio of 21%. Astec Life Sciences turned EBITDA positive at ₹5 crore, a sharp improvement from a loss last year. Management guided for continued momentum, with Astec targeting 15% revenue growth in FY27 and the crop protection business diversifying into new products. A strategic portfolio review is underway, with communication expected by early April. Key risks include unseasonal rains impacting crop protection and sustained milk procurement cost inflation in dairy.

Colored figures show movement against the previous available record.

Guidance to track

  • Management targets 15% revenue growth for Astec in FY27, led by CDMO segment growing faster than enterprise.
  • Management expects to sustain EBITDA margins in the 28-30% range for the crop protection business over the medium term.
  • Management reiterated guidance for Astec to achieve EBITDA breakeven for the full year FY26.
  • Management expects steady-state FFB tonnage growth of 12-15% CAGR, supported by acreage expansion and productivity improvements.

Risks flagged

  • Unseasonal rains and cyclones in Q3 affected crop protection volumes, and a base effect from co-marketing herbicide sales will impact Q4.
  • Dairy margins remain under pressure due to high milk procurement costs, with Maharashtra seeing higher inflation than other states.
  • Price pressure persists in the enterprise segment due to overcapacity in China, though it is stabilizing. Management monitors China's export tax policy changes.
  • Astec's initial FY27 revenue growth guidance of 15% is below historical aspirations of 25-30%, though management calls it a base case.

Key quotes

  • We are going to make some very clear sharp choices in the businesses which we clearly see as the top end of our investments and top end of our growth choices.
  • The turnaround is well and truly in play now.
  • We want to be a pure play branded retail organization in our foods businesses and have as less a play of trading or B2B businesses.

Research modules

Go one layer deeper.